⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1558607 | 0.64 | — | — | |
| SCHEMBL9966119 | 0.61 | — | — | |
| SCHEMBL15229041 | 0.61 | — | — | |
| SCHEMBL934117 | 0.55 | — | — | |
| SCHEMBL457848 | 0.54 | — | — | |
| SCHEMBL794331 | 0.52 | — | — | |
| SCHEMBL28026518 | 0.52 | GRIN2D (0.73) | — | |
| SCHEMBL8480598 | 0.51 | GRIN2D (0.45) | — | |
| SCHEMBL15063717 | 0.50 | GRIN2D (0.34) | — | |
| SCHEMBL1456606 | 0.49 | CYP1A2 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398254-A2 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | Memorial Sloan Kettering Cancer Center (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12023371-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11981703-B2 | Polynucleotide constructs | SIRIUS THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240131193-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-25 | — | — | US | disclosed |
| US-20240123035-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-18 | — | — | US | disclosed |
| EP-4351662-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| EP-2991655-B1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794585-A | Radioimmunoconjugates and checkpoint inhibitor combination therapies | 融合制药公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2013106414-A1 | TRYPTOLINE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-RX, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013106496-A1 | METHODS AND COMPOSITIONS FOR TARGETING AGENTS INTO AND ACROSS THE BLOOD-BRAIN BARRIER | modeRNA Therapeutics (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013106432-A1 | BENZHYDROL-PYRAZOLE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-RX, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013096709-A2 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2013090186-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090648-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |